Camrelizumab plus rivoceranib vs sorafenib as first-line therapy for unresectable hepatocellular carcinoma (uHCC): Final overall survival analysis of the phase 3 CARES-310 study.

被引：0

作者：

Vogel, Arndt

Chan, Stephen Lam

Ren, Zhenggang

Bai, Yuxian

Gu, Shanzhi

Lin, Xiaoyan

Chen, Zhendong

Jia, Weidong

Jin, Yongdong

Guo, Yabing

Hu, Xiaohua

Sultanbaev, Alexander Valerievich

Pazgan-Simon, Monika

Pisetska, Margaryta

Nip, Tsz Keung

Zhang, Haisong

Du, Jinghua

Cheng, Ann-Lii

Kaseb, Ahmed Omar

Qin, Shukui

机构：

[1] Hannover Med Sch, Dept Gastroenterol Hepatol & Endocrinol, Hannover, Germany

[2] Chinese Univ Hong Kong, Hong Kong, Peoples R China

[3] Fudan Univ, Liver Canc Inst, Zhongshan Hosp, Dept Hepat Oncol, Shanghai, Peoples R China

[4] Harbin Med Univ, Dept Gastroenterol, Canc Hosp, Harbin, Peoples R China

[5] Hunan Canc Hosp, Dept Intervent Radiol, Changsha, Peoples R China

[6] Fujian Med Univ, Dept Oncol, Union Hosp, Fuzhou, Peoples R China

[7] Anhui Med Univ, Dept Oncol, Affiliated Hosp 2, Hefei, Peoples R China

[8] Anhui Prov Hosp, Dept Gen Surg, Hefei, Peoples R China

[9] UESTC, Sichuan Canc Hosp & Inst, Dept Med Oncol, Affiliated Canc Hosp,Sch Med, Chengdu, Peoples R China

[10] Southern Med Univ, Nanfang Hosp, Dept Infect Dis, Liver Canc Ctr, Guangzhou, Peoples R China

[11] Guangxi Med Univ, Dept Med Oncol, Affiliated Hosp 1, Nanning, Peoples R China

[12] State Autonomous Budgetary Healthcare Inst, Republican Clin Oncol Dispensary, MoH Republ Bashkortostan, Ufa, Russia

[13] Wroclaw Med Univ, Dept Infect Dis & Hepatol, Wroclaw, Poland

[14] Cent Badan Klinicznych P Napora, Wroclaw, Poland

[15] Communal Non Profit Enterprise Reg Ctr Oncol, Dept Liver & Pancreas Gland Oncosurg, Kharkiv, Ukraine

[16] Jiangsu Hengrui Pharmaceut Co Ltd, Shanghai, Jiangsu, Peoples R China

[17] Natl Taiwan Univ Hosp, Taipei, Taiwan

[18] Univ Texas MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX, Peoples R China

[19] Canc Ctr Nanjing, Jinling Hosp, Nanjing, Peoples R China

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

4110

引用

页数：1

共 50 条

[21] Lenvatinib Plus Camrelizumab vs. Lenvatinib Monotherapy as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Cohort Study
Li, Qi
Cao, Mengran
Yuan, Guosheng
Cheng, Xiao
Zang, Mengya
Chen, Ming
Hu, Xiaoyun
Huang, Jing
Li, Rong
Guo, Yabing
Ruan, Jian
Chen, Jinzhang
FRONTIERS IN ONCOLOGY, 2022, 12
[22] Transarterial chemoembolization (TACE) combined with donafenib as first-line therapy for unresectable hepatocellular carcinoma (uHCC): A real-world clinical study.
Zhang, Weihong
Zhu, Bowen
Tang, Yiyang
Xue, Miao
Wu, Yanqin
Zhao, Yue
Fan, Wenzhe
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[23] Cost-effectiveness analysis of Tislelizumab vs Sorafenib as the first-line treatment of unresectable hepatocellular carcinoma
Chen, Qiuping
Sun, Quan
Zhang, Jing
Li, Baixue
Feng, Quansheng
Liu, Jibin
PLOS ONE, 2024, 19 (03):
[24] Final analysis of RATIONALE-301: Randomized, phase III study of tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma
Qin, S.
Kudo, M.
Meyer, T.
Finn, R. S.
Vogel, A.
Bai, Y.
Guo, Y.
Meng, Z.
Zhang, T.
Satoh, T.
Hiraoka, A.
Marino, D.
Assenat, E.
Wyrwicz, L.
Calvo Campos, M.
Hsing-Tao, K.
Boisserie, F.
Li, S.
Chen, Y.
Zhu, A. X.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S1402 - S1403
[25] Network meta-analysis (NMA) of lenvatinib vs key comparators in first-line unresectable hepatocellular carcinoma (uHCC)
Trueman, D.
Ndirangu, K.
Paine, A.
Pilkington, H.
ANNALS OF ONCOLOGY, 2023, 34 : S615 - S616
[26] Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC): First results from CheckMate 9DW.
Galle, Peter Robert
Decaens, Thomas
Kudo, Masatoshi
Qin, Shukui
Fonseca, Leonardo
Sangro, Bruno
Karachiwala, Hatim
Park, Joong-Won
Gane, Edward
Pinter, Matthias
Tai, David
Santoro, Armando
Pizarro, Gonzalo
Chiu, Chang-Fang
Schenker, Michael
He, Aiwu Ruth
Wang, Qi
Stromko, Caitlyn
Hreiki, Joseph
Yau, Thomas
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (17_SUPPL) : LBA4008 - LBA4008
[27] Phase II Study of First-Line Trebananib Plus Sorafenib in Patients with Advanced Hepatocellular Carcinoma
Abou-Alfa, Ghassan K.
Blanc, Jean-Frederic
Miles, Steven
Ganten, Tom
Trojan, Joerg
Cebon, Jonathan
Liem, Andre K.
Lipton, Lara
Gupta, Charu
Wu, Benjamin
Bass, Michael
Hollywood, Ellen
Ma, Jennifer
Bradley, Margaret
Litten, Jason
Saltz, Leonard B.
ONCOLOGIST, 2017, 22 (07): : 780 - +
[28] Penpulimab (Anti-PD-1) combined with anlotinib as first-line therapy for unresectable hepatocellular carcinoma (uHCC): Updated results from a phase Ib/II study.
Jiao Shun Chang
Bai Li
Dong Jiahong
Bai Chunmei
Hu Chunhong
Shen Liangfang
Qin Qun
Bai Yuxian
Fan Jia
Zang Aimin
Zhu Yanyun
Han Chun
Li Juan
Zhang Pengfei
Ye Sisi
Kang Xindan
Qiao Qian
Wang, Zhongmin Maxwell
Li Baiyong
Xia Yu
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
[29] Final analysis of serum biomarkers in patients (pts) from the phase III study of lenvatinib (LEN) vs sorafenib (SOR) in unresectable hepatocellular carcinoma (uHCC) [REFLECT]
Finn, R. S.
Kudo, M.
Cheng, A-L.
Wyrwicz, L.
Ngan, R.
Blanc, J. F.
Baron, A. D.
Vogel, A.
Ikeda, M.
Piscaglia, F.
Han, K-H.
Qin, S.
Minoshima, Y.
Kanekiyo, M.
Ren, M.
Dairiki, R.
Tamai, T.
Dutcus, C. E.
Funahashi, Y.
Evans, T. R. J.
ANNALS OF ONCOLOGY, 2018, 29
[30] Atezolizumab plus bevacizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma: a cost-effectiveness analysis
Hou, Yanli
Wu, Bin
CANCER COMMUNICATIONS, 2020, 40 (12) : 743 - 745

← 1 2 3 4 5 →